Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250636 · ClinicalTrials.gov registry record · Phase 1
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
A Phase 1 study, sponsored by Rockefeller University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04250636: Completed Phase 1 study, sponsored by Rockefeller University.
NCT04250636 is a Phase 1 study that has completed, run by Rockefeller University. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04250636, a Phase 1 study, has completed, sponsored by Rockefeller University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human immunodeficiency virus (HIV)-infected individuals.
Primary Outcome
The number of participants with treatment-related solicited and unsolicited grade 3 and serious adverse events (including confirmed laboratory abnormalities).
Interventions
- DRUG 3BNC117-LS
- DRUG 10-1074-LS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2022-02-11 |
| Phase | Phase 1 |
What the finished NCT04250636 record still lists
NCT04250636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which 3BNC117-LS is the first listed.
NCT04250636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04250636 about?
NCT04250636 is a clinical study titled "3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals". The proposed study is a phase 1, open label, single arm study to evaluate the safety, pharmacokinetics and antiviral activity of single intravenous infusions of 3BNC117-LS and 10-1074-LS, each monoclonal antibody (mAb) dosed at 30 mg/kg in viremic human immunodeficiency virus (HIV)-infected individu...
What is the current status of trial NCT04250636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-10-13. Estimated completion is 2022-02-11.
What interventions are being tested in trial NCT04250636?
The interventions under investigation include: 3BNC117-LS (DRUG), 10-1074-LS (DRUG).
Who is sponsoring clinical trial NCT04250636?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04250636's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI